NO20092741L - DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser - Google Patents
DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelserInfo
- Publication number
- NO20092741L NO20092741L NO20092741A NO20092741A NO20092741L NO 20092741 L NO20092741 L NO 20092741L NO 20092741 A NO20092741 A NO 20092741A NO 20092741 A NO20092741 A NO 20092741A NO 20092741 L NO20092741 L NO 20092741L
- Authority
- NO
- Norway
- Prior art keywords
- antagonists
- treatment
- neurological disorders
- antibodies
- mammalian
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87152806P | 2006-12-22 | 2006-12-22 | |
| US90084807P | 2007-02-12 | 2007-02-12 | |
| PCT/US2007/088521 WO2008080045A2 (en) | 2006-12-22 | 2007-12-21 | Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092741L true NO20092741L (no) | 2009-09-21 |
Family
ID=39535220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092741A NO20092741L (no) | 2006-12-22 | 2009-07-21 | DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100203044A1 (es) |
| EP (1) | EP2094732A2 (es) |
| JP (1) | JP2010514700A (es) |
| KR (1) | KR20090094854A (es) |
| AR (1) | AR064501A1 (es) |
| AU (1) | AU2007336770A1 (es) |
| BR (1) | BRPI0719459A2 (es) |
| CA (1) | CA2671903A1 (es) |
| CL (1) | CL2007003793A1 (es) |
| CO (1) | CO6210755A2 (es) |
| MX (1) | MX2009006685A (es) |
| NO (1) | NO20092741L (es) |
| NZ (1) | NZ577436A (es) |
| PE (1) | PE20081546A1 (es) |
| RU (1) | RU2009128039A (es) |
| SG (1) | SG177924A1 (es) |
| TW (1) | TW200844113A (es) |
| WO (1) | WO2008080045A2 (es) |
| ZA (1) | ZA201004219B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0921837A2 (pt) * | 2008-11-25 | 2016-01-12 | Biogen Idec Inc | anticorpos isolados ou fragmentos de antígeno de ligação dos mesmos que podem se ligar especificamente a um polipeptídio dr6, métodos in vitro de promover a sobrevivência de uma célula do sistema nervoso, usos de um antagonista dr6 e métodos in vitro de inibir a ligação de dr6 com p75 |
| TW201034684A (en) * | 2009-02-18 | 2010-10-01 | Genentech Inc | Method for inhibiting neurodegeneration |
| KR20120103587A (ko) * | 2009-11-12 | 2012-09-19 | 제넨테크, 인크. | 수상돌기 소극 밀도를 증진시키는 방법 |
| MX359070B (es) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Composiciones anti-ngf y uso de las mismas. |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US20120238465A1 (en) * | 2011-03-17 | 2012-09-20 | Joseph Audie | Drug screening target for alzheimer's disease and method of screening potential drugs |
| CN102708565A (zh) * | 2012-05-07 | 2012-10-03 | 深圳市贝尔信智能系统有限公司 | 一种前景检测的方法、装置和系统 |
| WO2015057736A1 (en) * | 2013-10-14 | 2015-04-23 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
| US10370450B2 (en) | 2013-11-20 | 2019-08-06 | National University Corporation Hokkaido University | Anti-DR6 antibodies and methods of immune regulation |
| US20170174734A1 (en) * | 2014-03-12 | 2017-06-22 | Temple University-Of The Commonwealth System Of Higher Education | DR6 Receptor Mediates the Leukemia Differentiation Activity of Angiocidin: A Potent Anti-Tumor Peptide |
| SG11201706809WA (en) | 2015-03-16 | 2017-09-28 | Regeneron Pharma | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
| CN112472796A (zh) * | 2015-03-26 | 2021-03-12 | 苏州澳宗生物科技有限公司 | 使用p75ecd和/或p75诊断或治疗神经障碍的方法 |
| AU2017261369A1 (en) * | 2016-05-06 | 2018-11-15 | Abbvie Stemcentrx Llc | Novel anti-TNFRSF21 antibodies and methods of use |
| KR102351126B1 (ko) * | 2019-12-03 | 2022-01-13 | 재단법인대구경북과학기술원 | App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3702789A1 (de) * | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
| EP1132471A3 (de) * | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| JPH05506990A (ja) * | 1990-04-24 | 1993-10-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | プロテアーゼ ネキシン―２の精製、検出、及び使用方法 |
| US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
| US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| JP3277211B2 (ja) * | 1991-11-12 | 2002-04-22 | プラナ・バイオテクノロジー・リミテッド | アルツハイマー病の試験方法と治療方法 |
| CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US6013476A (en) * | 1997-04-02 | 2000-01-11 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor TR7 |
| US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| US6949358B1 (en) | 1997-06-11 | 2005-09-27 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor TR9 |
| US7378507B2 (en) * | 1997-09-18 | 2008-05-27 | Genentech, Inc. | PRO217 polypeptides |
| US6194151B1 (en) * | 1997-09-26 | 2001-02-27 | Millenium Pharmaceuticals, Inc. | Molecules of the TNF receptor superfamily and uses therefor |
| FR2778858B1 (fr) * | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
| US6916907B1 (en) * | 1998-10-23 | 2005-07-12 | Curagen Corporation | Nucleic acids encoding osteoprotegern-like proteins and methods of using same |
| US6423494B1 (en) * | 1999-03-25 | 2002-07-23 | Millennium Pharmaceuticals, Inc. | DR6 and uses thereof |
| AT5874U1 (de) * | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| AU2002255881A1 (en) * | 2001-03-23 | 2002-10-08 | University Of Utah Research Foundation | Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use |
| WO2003039467A2 (en) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
| WO2003040183A2 (en) * | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
| EP1455825A4 (en) | 2001-12-17 | 2006-05-31 | Lilly Co Eli | TREATMENT OF B-CELL-MEDIATED DISEASES BY MODULATION OF THE DR6 ACTIVITY |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| ES2301280A1 (es) * | 2005-05-16 | 2008-06-16 | Fina Biotech S.L.U. | Metodo para diagnosticar la enfermedad de alzheimer. |
| US20100099609A1 (en) * | 2008-07-28 | 2010-04-22 | Buck Institute For Age Research | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE |
| KR20120103587A (ko) * | 2009-11-12 | 2012-09-19 | 제넨테크, 인크. | 수상돌기 소극 밀도를 증진시키는 방법 |
-
2007
- 2007-12-21 NZ NZ577436A patent/NZ577436A/en not_active IP Right Cessation
- 2007-12-21 AU AU2007336770A patent/AU2007336770A1/en not_active Abandoned
- 2007-12-21 JP JP2009543252A patent/JP2010514700A/ja active Pending
- 2007-12-21 KR KR1020097015353A patent/KR20090094854A/ko not_active Application Discontinuation
- 2007-12-21 RU RU2009128039/10A patent/RU2009128039A/ru not_active Application Discontinuation
- 2007-12-21 US US12/520,044 patent/US20100203044A1/en not_active Abandoned
- 2007-12-21 WO PCT/US2007/088521 patent/WO2008080045A2/en active Application Filing
- 2007-12-21 EP EP07869737A patent/EP2094732A2/en not_active Withdrawn
- 2007-12-21 AR ARP070105866A patent/AR064501A1/es not_active Application Discontinuation
- 2007-12-21 TW TW096149573A patent/TW200844113A/zh unknown
- 2007-12-21 MX MX2009006685A patent/MX2009006685A/es not_active Application Discontinuation
- 2007-12-21 BR BRPI0719459-5A2A patent/BRPI0719459A2/pt not_active IP Right Cessation
- 2007-12-21 CA CA002671903A patent/CA2671903A1/en not_active Abandoned
- 2007-12-21 SG SG2011096492A patent/SG177924A1/en unknown
- 2007-12-21 CL CL200703793A patent/CL2007003793A1/es unknown
-
2008
- 2008-01-02 PE PE2008000033A patent/PE20081546A1/es not_active Application Discontinuation
-
2009
- 2009-07-16 CO CO09074363A patent/CO6210755A2/es not_active Application Discontinuation
- 2009-07-21 NO NO20092741A patent/NO20092741L/no not_active Application Discontinuation
-
2010
- 2010-06-14 ZA ZA2010/04219A patent/ZA201004219B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008080045A3 (en) | 2008-09-12 |
| EP2094732A2 (en) | 2009-09-02 |
| US20100203044A1 (en) | 2010-08-12 |
| NZ577436A (en) | 2012-05-25 |
| PE20081546A1 (es) | 2008-12-22 |
| CL2007003793A1 (es) | 2008-07-25 |
| TW200844113A (en) | 2008-11-16 |
| SG177924A1 (en) | 2012-02-28 |
| ZA201004219B (en) | 2013-02-27 |
| CO6210755A2 (es) | 2010-10-20 |
| JP2010514700A (ja) | 2010-05-06 |
| WO2008080045A2 (en) | 2008-07-03 |
| KR20090094854A (ko) | 2009-09-08 |
| MX2009006685A (es) | 2009-07-27 |
| RU2009128039A (ru) | 2011-01-27 |
| AU2007336770A1 (en) | 2008-07-03 |
| BRPI0719459A2 (pt) | 2014-02-04 |
| CA2671903A1 (en) | 2008-07-03 |
| AR064501A1 (es) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092741L (no) | DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser | |
| NO20083324L (no) | Multisykliske aminosyrederivater og anvendelse derav | |
| EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| WO2006060314A3 (en) | Generation of replication competent viruses for therapeutic use | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| AU2005253776A8 (en) | Screening methods using c-Abl, Fyn and Syk in combination with tau protein | |
| WO2002064748A8 (en) | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| IL177015B (en) | Isolated human rpe cells and their use for the treatment of retinal degenerative diseases | |
| WO2006105252A3 (en) | Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells | |
| NO20051030L (no) | Funksjonelle kardiomyocytter fra humane embryonale stamceller | |
| WO2007044323A3 (en) | Fusion proteins for blood-brain barrier delivery | |
| DE602005006990D1 (de) | Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen | |
| WO2005115548A3 (en) | Treating depressive disorders with carbonic anhydrase activators | |
| WO2005046570A3 (en) | Human stem cell materials and methods | |
| WO2004044168A3 (en) | Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities | |
| WO2008034016A3 (en) | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins | |
| WO2007005502A3 (en) | Methods and compositions for treating diseases targeting cdcp1 | |
| ATE359508T1 (de) | Screening-verfahren unter verwendung von zebrafisch und der blut-hirn-schranke | |
| DE602006013143D1 (de) | Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate | |
| DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit | |
| WO2002092013A3 (en) | Methods for treating liver disease and liver damage with growth hormone and foxm1b | |
| ATE485377T1 (de) | Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen | |
| WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| DE602006008460D1 (de) | NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Reestablishment of rights (par. 72 patents act) | ||
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |